INTENSITY THERAPEUTICS, INC.

Intensity Therapeutics (INTS) shows no cyber incidents or material red-flag 8-K filings in our 90-day monitoring window. However, low signal in this recent period does not indicate the absence of structural risk; the company operates in the capital-intensive biotech sector where financing history, equity dilution patterns, and cash runway are critical underwriting factors. The full $49 Report pulls 12 months of SEC filings, calculates dilution risk scores, flags 8-K context, and surfaces AI-detected risk signals that shape long-term equity value. Access the complete analysis to understand burn rate, financing needs, and shareholder impact.